TOVX · Theriva Biologics, Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these financial statements are issued. The Company's ability to continue as a going concern is dependent upon the Company's ability to raise additional debt and equity capital or secure a potential license or strategic relationship that can help fund its clinical development activities. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to the Company. These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-01-05 | Kraws Jeffrey J |
Co-President |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
75,000 |
| 2026-01-05 | Wolf Jeffrey Alan |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
75,000 |
| 2026-01-05 | MONAHAN JOHN J |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
75,000 |
| 2026-01-05 | SHALLCROSS STEVEN A |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 36 months. |
Stock Options (right to buy)
|
475,000 |
| 2025-04-29 | MONAHAN JOHN J |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
25,000 |
| 2025-04-29 | Kraws Jeffrey J |
Co-President |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
25,000 |
| 2025-04-29 | Wolf Jeffrey Alan |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
25,000 |
| 2025-04-29 | SHALLCROSS STEVEN A |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 36 months. |
Stock Options (right to buy)
|
190,000 |
| 2023-12-14 | Wolf Jeffrey Alan |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
110,000 |
| 2023-12-14 | Kraws Jeffrey J |
Co-President |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
110,000 |
| 2023-12-14 | SHALLCROSS STEVEN A |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 36 months. |
Stock Options (right to buy)
|
700,000 |
| 2023-12-14 | MONAHAN JOHN J |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
110,000 |
| 2023-06-07 | SHALLCROSS STEVEN A |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6699 through $0.699, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Common Stock
|
14,000 |
| 2023-06-06 | SHALLCROSS STEVEN A |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6015 through $0.6659, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Common Stock
|
26,000 |
| 2023-02-10 | SHALLCROSS STEVEN A |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.02 through $1.05, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Common Stock
|
25,000 |
| 2023-02-02 | SHALLCROSS STEVEN A |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.9349 through $0.9499, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Common Stock
|
25,000 |
| 2023-01-25 | SHALLCROSS STEVEN A |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.860 through $0.875, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Common Stock
|
25,000 |
| 2023-01-20 | SHALLCROSS STEVEN A |
Director |
Buy↑
|
Common Stock
|
25,000 |
| 2022-12-29 | SHALLCROSS STEVEN A |
Director |
Buy↑
|
Common Stock
|
100,000 |
| 2022-12-15 | MONAHAN JOHN J |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
100,000 |
| 2022-12-15 | SHALLCROSS STEVEN A |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 36 months. |
Stock Options (right to buy)
|
475,000 |
| 2022-12-15 | Kraws Jeffrey J |
Co-President |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
100,000 |
| 2022-12-15 | Tufaro Francis |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 36 months. |
Stock Options (right to buy)
|
100,000 |
| 2022-12-15 | Wolf Jeffrey Alan |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
100,000 |
| 2021-12-23 | MONAHAN JOHN J |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
200,000 |
| 2021-12-23 | Kraws Jeffrey J |
Co-President |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
200,000 |
| 2021-12-23 | Wolf Jeffrey Alan |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 12 months. |
Stock Options (right to buy)
|
200,000 |
| 2021-12-23 | SHALLCROSS STEVEN A |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
These stock options vest pro rata on a monthly basis over 36 months. |
Stock Options (right to buy)
|
650,000 |
| 2021-05-10 | SHALLCROSS STEVEN A |
Director |
Buy↑
|
Common Stock
|
50,000 |
| 2020-12-30 | Kraws Jeffrey J |
Co-President |
Award↑
Filing footnotes — Stock Options (Direct)
These stock options will vest pro rata on a monthly basis over 12 months. |
Stock Options
|
150,000 |
| 2020-12-30 | Wolf Jeffrey Alan |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Options (Direct)
These stock options will vest pro rata on a monthly basis over 12 months. |
Stock Options
|
150,000 |
| 2020-12-30 | SHALLCROSS STEVEN A |
Director |
Award↑
Filing footnotes — Stock Options (Direct)
These stock options will vest pro rata on a monthly basis over 36 months. |
Stock Options
|
450,000 |
| 2020-12-30 | MONAHAN JOHN J |
Director |
Award↑
Filing footnotes — Stock Options (Direct)
These stock options will vest pro rata on a monthly basis over 12 months. |
Stock Options
|
150,000 |